Monthly Prescribing Reference

Relistor Injection

Methylnaltrexone bromide 8mg/0.4mL, 12mg/0.6mL; soln for SC inj. Opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including chronic pain related to prior cancer or its ...
FiercePharma

FDA Approves RELISTOR® Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain

Marketing Approval Expands Treatment to Include Nearly 11 Million Patients Who Experience Opioid-Induced Constipation While Taking Opioids for Chronic Non-Cancer Pain RALEIGH, N.C. & TARRYTOWN, N.Y.-- ...
Monthly Prescribing Reference

sNDA Accepted for Relistor for Opioid Induced Constipation in Non-Cancer Patients

Progenics Pharmaceuticals and Salix Pharmaceuticals announced that the FDA has accepted for filing a supplemental New Drug Application (sNDA) for Relistor (methylnaltrexone bromide) Subcutaneous ...
The Trentonian

Salix Pharmacetuicals Will Present Scientific Data Featuring Post Hoc Analyses For RELISTOR(R) (Methylnaltrexone Bromide) At ASRA’s 46th Annual Spring Meeting

RELISTOR(R) (methylnaltrexone bromide) is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic ...
Business Wire

Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for RELISTOR ®

RELISTOR Subcutaneous Injection is approved in the United States for the treatment of OIC in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not ...